文献速递皮肤肿瘤

利用自噬克服转移性黑色素瘤中丝裂原活化蛋白激酶激酶抑制剂诱导的耐药

Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
PubMed 文献 · Br J Dermatol · 2018-11-25

研究探讨黑色素瘤对曲美替尼耐药过程中CD271的调控模式及耐药与促生存自噬诱导的关联。结果显示CD271与自噬信号在III期原发性黑色素瘤中较良性痣增加,曲美替尼诱导的CD271降低自噬流并激活促生存自噬导致耐药,靶向自噬可能使耐药细胞对MEKi的细胞毒性作用重新敏感。

要点

  • CD271和自噬信号在III期原发性黑色素瘤中较良性痣增加。
  • 曲美替尼诱导的CD271降低自噬流,激活促生存自噬并导致MEKi耐药。
  • 靶向自噬可能使耐药黑色素瘤细胞对MEKi的细胞毒性作用重新敏感。

核心结论

  • 结果揭示MEKi诱导耐药的新机制,并提示靶向自噬可能是使耐药黑色素瘤细胞对MEKi细胞毒性作用重新敏感的可转化方法。

研究设计与样本

  • 对人痣和原发性恶性黑色素瘤肿瘤进行CD271和p62免疫组化。
  • 用蛋白质印迹分析黑色素瘤亚群中CD271、p62和LC3的表达。
  • 用流式细胞术和免疫荧光显微镜评估曲美替尼诱导的细胞死亡和CD271表达。
  • 用MTS活力测定和斑马鱼异种移植分别评估CD271和自噬调节对曲美替尼耐药黑色素瘤细胞存活和侵袭的影响。

主要发现

  • CD271和自噬信号在III期原发性黑色素瘤中较良性痣增加。
  • 体外研究显示BRAF突变黑色素瘤的MEKi诱导细胞毒性自噬,随后出现表达CD271的亚群。
  • 曲美替尼诱导的CD271降低自噬流,导致促生存自噬激活和MEKi耐药发生。
  • 用RNA干扰和小分子抑制剂靶向CD271治疗表达CD271的黑色素瘤亚群减少了MEKi耐药的发生。
  • 临床可用的自噬调节剂包括Δ9-四氢大麻酚和Vps34降低了MEKi耐药黑色素瘤细胞的存活。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with malignant melanoma often relapse after treatment with BRAF and/or mitogen-activated protein kinase kinase (MEK) inhibitors (MEKi) owing to development of drug resistance. OBJECTIVES: To establish the temporal pattern of CD271 regulation during development of resistance by melanoma to trametinib, and determine the association between development of resistance to trametinib and induction of prosurvival autophagy. METHODS: Immunohistochemistry for CD271 and p62 was performed on human naevi and primary malignant melanoma tumours. Western blotting was used to analyse expression of CD271, p62 and LC3 in melanoma subpopulations. Flow cytometry and immunofluorescence microscopy was used to evaluate trametinib-induced cell death and CD271 expression. MTS viability assays and zebrafish xenografts were used to evaluate the effect of CD271 and autophagy modulation on trametinib-resistant melanoma cell survival and invasion, respectively. RESULTS: CD271 and autophagic signalling are increased in stage III primary melanomas vs. benign naevi. In vitro studies demonstrate MEKi of BRAF-mutant melanoma induced cytotoxic autophagy, followed by the emergence of CD271-expressing subpopulations. Trametinib-induced CD271 reduced autophagic flux, leading to activation of prosurvival autophagy and development of MEKi resistance. Treatment of CD271-expressing melanoma subpopulations with RNA interference and small-molecule inhibitors to CD271 reduced the development of MEKi resistance, while clinically applicable autophagy modulatory agents - including Δ9-tetrahydrocannabinol and Vps34 - reduced survival of MEKi-resistant melanoma cells. Combined MEK/autophagy inhibition also reduced the invasive and metastatic potential of MEKi-resistant cells in an in vivo zebrafish xenograft. CONCLUSIONS: These results highlight a novel mechanism of MEKi-induced drug resistance and suggest that targeting autophagy may be a translatable approach to resensitize drug-resistant melanoma cells to the cytotoxic effects of MEKi.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Verykiou S, Alexander M, Edwards N, et al. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2018. PMID: 30339727. doi:10.1111/bjd.17333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。